Your browser doesn't support javascript.
loading
Ultrasound-guided percutaneous ablation treatment for current hepatoblastoma: initial single-center experience / 中国医师杂志
Journal of Chinese Physician ; (12): 813-816, 2017.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-620933
Responsible library: WPRO
ABSTRACT
Objective To summarize the first experience with ultrasound-guided percutaneous ab lation treatment (PAT) for recurrent hepatoblastoma (HB) after liver resection in children.Methods From August 2013 to April 2015,PAT was used to treat 6 children with a total of 9 recurrent HB,including 5 patients with 8 tumors in the liver and 1 patient with 1 tumor in the lung.The mean size of ablated tumors was (1.5 ± 0.8) cm,and the tumor size range was 0.7 cm to 3.1 cm.Results Four patients were performed percutaneous radiofrequency ablation (RFA) for recurrent HB;and 2 patients were performed percutaneous ethanol injection (PEI).Ablation success was achieved in all patients (6/6,100%).The complete ablation rate after the first ablation session was 88.9% (8/9) on a tumor-by-tumor basis.Only 1 patient developed a fever with temperature > 39 ℃;it was resolved by conservative therapy.During the follow-up period of 5-30 months,3 patients died to tumor progression.The 1-and 2-year overall survival rates after ablation were 83.3% and 41.7%,respectively.Conclusions PAT is a safe and promising therapy for children with recurrent HB after liver resection,and further investigation in large-scale randomized clinical trials is required to determine its role in the treatment of this disease.

Full text: Available Database: WPRIM (Western Pacific) Type of study: Controlled clinical trial Language: Chinese Journal: Journal of Chinese Physician Year: 2017 Document type: Article
Full text: Available Database: WPRIM (Western Pacific) Type of study: Controlled clinical trial Language: Chinese Journal: Journal of Chinese Physician Year: 2017 Document type: Article
...